$41.1 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$2.72 BillionTotal revenue in the last quarter.
$246 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$1.81Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.905 (1.12%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
44.68xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$367 MillionEarnings before interest expenses and taxes in the last quarter.
50,000The number of full time employees.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Baxter International (NYSE:BAX) is scheduled to be releasing its earnings data before the market opens on Thursday, October 29th. Analysts expect Baxter International to post earnings of $0.71 per ...Daily Political, 8 days ago
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference via we...Business Wire, 14 days ago
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, supports interim findings of an ongoing prospective study, “Persistent Hypermetabolism ...Business Wire, 15 days ago